ResMed has declared a quarterly dividend of USD 0.066 per share for holders of Chess Depositary Instruments trading on the ASX. The announcement, made on 7 August 2026, represents the company’s Q3 2026 distribution and carries important implications for Australian investors holding the security. The ex-date of 19 August 2026 marks the final deadline for investors to hold the security in order to qualify for the payment.
For those unfamiliar with the structure, ResMed’s Australian listing operates through CDIs rather than direct share ownership. Each CDI represents one-tenth of an underlying NYSE share, reflecting the 10:1 ratio between the two securities. This means Australian investors will receive an AUD equivalent to USD 0.66 per underlying share, converted at the exchange rate on the record date of 20 August 2026. The payment itself is scheduled for 24 September 2026, providing investors with clear visibility on timing.
The dividend is classified as ordinary and unfranked, with zero franking credits attached. This reflects ResMed’s status as a foreign company with USD earnings, and investors should note the full amount is subject to a 30 percent withholding tax. The unfranked nature means Australian taxpayers cannot access franking credits to offset tax liabilities, unlike distributions from domestic companies. For individuals in high tax brackets, this may reduce the after-tax yield materially compared to franked alternatives.
The USD 0.066 per share declaration relates to the quarter ended 30 June 2026 and represents the company’s continued commitment to returning capital to shareholders. For context on ResMed’s dividend policy, investors should review historical payout ratios and management guidance around capital allocation priorities. The company operates in the healthcare technology sector with recurring revenue streams, which typically supports more predictable dividend policies than cyclical industries.
Australian investors holding CDIs should ensure they understand the timing requirements to qualify for the payment. The ex-date of 19 August 2026 is the critical threshold, as shareholders must own the security before this date to receive the dividend. Those considering purchases should factor in both the ex-date mechanics and the current AUD/USD exchange rate when assessing expected returns. The withholding tax treatment and unfranked status should also be incorporated into portfolio tax planning, particularly for investors managing overall tax efficiency across multiple holdings. This announcement has been flagged as price sensitive material by the ASX and should be considered as such by investors making portfolio decisions.
View the full ASX announcement (PDF)
About ResMed Inc (ASX: RMD)
ResMed Inc develops and manufactures medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders including sleep apnea, chronic obstructive pulmonary disease, and neuromuscular disease. The company supplies flow generators, masks, and accessories globally, with the majority of revenue derived from operations in the Americas. ResMed also pursues digital health initiatives and acquisitions to enhance clinical data offerings for patients, healthcare providers, and payers in out-of-hospital settings.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
